Xeraya Capital
Directory: VC Companies in Malaysia
Overview
| Field |
Details |
| Founded |
2010 |
| HQ |
Kuala Lumpur, Malaysia |
| Type |
Venture Capital + Private Equity |
| Specialisation |
Life Sciences, Biotech, Healthtech |
| Geography |
Global investments, Malaysia impact focus |
Xeraya Capital is Malaysia's leading life sciences-focused venture capital and private equity firm. It invests globally in healthcare innovation with a specific mandate to drive value creation in Malaysia's bioeconomy. Xeraya's portfolio spans pharmaceutical tech, medical devices, digital health, agricultural biotech, and clinical-stage biotech companies. It is backed by a consortium of Malaysian institutional investors and family offices with a global outlook.
Investment Focus
Stages
- Seed (select)
- Series A
- Series B
- Late-stage / Pre-IPO
Sectors
- Pharmaceutical tech & drug development
- Medical devices & diagnostics
- Digital health & telemedicine
- Biotech & synthetic biology
- Agritech & agricultural biotech
- Nutraceuticals & wellness tech
Geographies
- USA, Europe, Israel (global biotech hubs)
- Malaysia (local value creation)
- ASEAN (healthtech expansion plays)
Ticket Sizes
- $1M–$20M depending on stage
- PE: $10M–$50M+
Distinctive Approach
- Cross-border bridge: Brings globally-validated life sciences innovations to Malaysia and ASEAN
- Clinical expertise: Team includes MDs and PhD scientists alongside investment professionals
- Government alignment: Works closely with MoST, MOSTI, and Bioeconomy Corporation
- Technology transfer: Helps international biotech firms establish Malaysia operations
Portfolio Highlights
| Company |
Sector |
Country |
| Various biotech |
Drug development |
USA, Israel |
| Healthtech companies |
Digital health |
Malaysia/SEA |
| Agritech |
Agricultural biotech |
Malaysia |
| Medical devices |
Diagnostics |
Global |
Team & Leadership
| Name |
Role |
| Wong Mun Choong |
CEO & Managing Partner |
| Investment Team |
Science + finance backgrounds |
How to Pitch
- Email info@xeraya.com — pitch deck should include clinical data, IP status, and regulatory pathway
- Essential: proof of concept or clinical-stage data, clear IP ownership, commercialisation plan for Malaysia/ASEAN
- They do not invest in pure digital health without a life sciences component
- International companies: highlight Malaysia expansion opportunity (manufacturing, clinical trials, distribution)
Notes & Recent News
- Published the comprehensive Malaysia Venture Capital Roadmap 2024–2030
- Active in MoST and Bioeconomy Corporation working groups
- One of the few Malaysian VCs with genuine biotech domain expertise
- Malaysia's bioeconomy ambitions make Xeraya a strategic partner for life sciences founders
Last updated: 2026-05-06